Briakinumab: Phase III data

The double-blind Phase III M06-890 trial in 1,465 patients showed that briakinumab met the co-primary endpoints of a significantly greater proportion of patients achieving a PASI 75 response at week 12 (80.7% vs. 4.5%, p<0.001), and of a significantly greater proportion of patients with a PGA score of 0 or 1 at week 12 (76% vs. 4.3%, p<0.001). Briakinumab every 4 weeks and every 12 weeks also met the co-primary endpoint of a significantly greater proportion of patients with a PGA score of 0 or 1 at week 52 (79.2% and 41.6%, respectively, vs. 6% for placebo; p<0.001 or both). ...